© 2004 Foundation for Promotion of Cancer Research
Characteristics of Patients with Prostate Cancer Who Have Initially been Treated by Hormone Therapy in Japan: J-CaP Surveillance
1 Department of Urology, University of Tsukuba, Tsukuba, Ibaraki, 2 Department of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, 3 Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, 4 Department of Urology, The University of Tokushima School of Medicine, Tokushima, 5 Department of Urology, Faculty of Medicine, The University of Tokyo, Tokyo, 6 Department of Urology, Sapporo Medical University, School of Medicine, Sapporo, 7 Department of Urology, University of Kyushu, Fukuoka, 8 Department of Urology, Nara Medical School, Kashihara, Nara, 9 Department of Urology, Keio University School of Medicine, Tokyo and 10 Department of Urology, Gunma University School of Medicine, Maebashi, Japan
Objective: Hormone therapy for prostate cancer has empirically prevailed in Japan. We planned to evaluate the trends and outcome of hormone therapy for establishing an adequate guideline.
Methods: Patients with prostate cancer who were initially treated by hormone therapy were registered through the J-CaP registration system. This report summarizes the background factors.
Results: From January 2001 to October 2003, 17 872 patients were registered from 395 institutes throughout Japan. The background factors of 17 312 patients were analyzed. The 17 872 patients were estimated as composing more than half of newly diagnosed prostate cancer patients in Japan. Of these, 22.9, 35.1, 32.9 and 8.6% belonged to T1, T2, T3 and T4, respectively. For the purposes of hormone therapy, 77.5% was primary hormone therapy. Neoadjuvant setting and adjuvant setting were 18.1 and 4.3%, respectively. About 60% of the hormone therapy was combined hormone therapy with LH-RHa plus anti-androgens.
Conclusion: Irrespective of patients’ age, TNM, stage of illness, or histological background, the majority of prostate cancer patients in Japan are receiving hormone therapy. It is necessary to evaluate whether this trend is merely a continuation of past experience of Japanese urologists or if there is a difference in the profile of effect and side-effect in the case of Japanese patients compared to therapy given in Westerners.
+ For reprints and all correspondence: Hideyuki Akaza, Department of Urology, Faculty of Medicine, Institute of Clinical Medicine, University of Tsukuba, 1–1–1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan. E-mail: akazah{at}md.tsukuba.ac.jp
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. R. Cooperberg, S. Hinotsu, M. Namiki, K. Ito, J. Broering, P. R. Carroll, and H. Akaza Risk Assessment Among Prostate Cancer Patients Receiving Primary Androgen Deprivation Therapy J. Clin. Oncol., September 10, 2009; 27(26): 4306 - 4313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hinotsu, H. Akaza, M. Usami, O. Ogawa, S. Kagawa, T. Kitamura, T. Tsukamoto, S. Naito, M. Namiki, Y. Hirao, et al. Current Status of Endocrine Therapy for Prostate Cancer in Japan Analysis of Primary Androgen Deprivation Therapy on the Basis of Data Collected by J-CaP Jpn. J. Clin. Oncol., October 26, 2007; (2007) hym098v1. [Abstract] [Full Text] [PDF]
|
|